黑料网

Transplant rejection; Genetics; HLA; Non-HLA genes; Acute rejection; Chronic rejection; Immunogenetics; Polymorphism; Single nucleotide polymorphisms (SNPs); Personalized medicine

Introduction

Organ transplantation offers a definitive treatment for end-stage organ failure. However, the recipient's immune system recognizes the transplanted organ as foreign, initiating an immune response that can lead to rejection. This complex process is influenced by a multitude of factors, including the genetic makeup of both the donor and the recipient [1]. Understanding the genetic basis of transplant rejection is crucial for developing strategies to predict rejection risk, personalize immunosuppressive regimens, and ultimately improve long-term graft survival. The major histocompatibility complex (MHC), located on chromosome 6 in humans, encodes the HLA genes, which play a central role in antigen presentation and immune recognition [2].  

Description

This review summarizes current research on genetic factors involved in transplant rejection. A comprehensive literature search was conducted using databases such as PubMed, MEDLINE, and Google Scholar, using keywords including "transplant rejection," "genetics," "HLA," "non-HLA genes," "acute rejection," "chronic rejection," and related terms. Studies focusing on human solid organ transplantation and investigating the association between genetic polymorphisms and rejection outcomes were included. Both candidate gene studies and genome-wide association studies (GWAS) were considered.

The HLA genes are the most extensively studied genetic factors in transplantation. HLA matching, particularly at the HLA-A, HLA-B, and HLA-DR loci, has been a cornerstone of transplant practice for decades, demonstrating a strong association with acute rejection, especially in kidney transplantation [3]. Mismatches at these loci can lead to strong T cell responses against the graft. However, with the advent of more potent immunosuppressive agents, the impact of HLA mismatching on acute rejection has somewhat diminished in some organ transplants, although it still plays a crucial role in chronic rejection and antibody-mediated rejection (AMR). Beyond classical HLA loci, non-classical HLA genes, such as HLA-G, have also been implicated in influencing transplant outcomes [4]. HLA-G is known for its immunomodulatory properties and has been associated with reduced rejection risk.  

Beyond the MHC region, numerous non-HLA genes have been identified as potential contributors to transplant rejection. These genes are involved in various aspects of the immune response, including cytokine production, T cell activation, and inflammation. Polymorphisms in genes encoding cytokines such as TNF-α, IL-10, and IFN-γ have been associated with altered rejection risk [5]. Studies have also investigated the role of genes involved in the innate immune system, such as those encoding Toll-like receptors (TLRs), in influencing transplant outcomes. Single nucleotide polymorphisms (SNPs) in these genes can affect their expression or function, potentially modulating the immune response to the graft.  

GWAS have emerged as a powerful tool for identifying novel genetic associations with complex traits, including transplant rejection. These studies have identified several non-HLA loci associated with rejection risk, providing further insights into the genetic architecture of this complex trait. For example, studies have linked variations in genes involved in T cell signaling pathways to rejection episodes [6].  

Discussion

The research reviewed highlights the complex interplay of genetic factors in transplant rejection. While HLA genes remain the most significant genetic factors, the growing body of evidence implicates numerous non-HLA genes in influencing transplant outcomes. These findings have important implications for personalized medicine in transplantation. By identifying individuals at high risk of rejection based on their genetic profile, clinicians can tailor immunosuppressive regimens to minimize rejection risk while avoiding over-immunosuppression and associated side effects [7].  

The role of genetic factors in chronic rejection is an area of ongoing research. While acute rejection is primarily mediated by T cells, chronic rejection is a more complex process involving both cellular and humoral immunity, as well as non-immunological factors. Genetic predisposition may influence the development of chronic allograft vasculopathy (CAV) and interstitial fibrosis/tubular atrophy (IFTA), the major pathological features of chronic rejection. Studies have investigated the association between genetic polymorphisms and the development of these lesions [8].  

The impact of donor genetics on recipient outcomes is also an important area of investigation. While most studies have focused on recipient genetics, donor genetic variations can also influence graft function and susceptibility to rejection. For instance, donor genetic variations in genes involved in oxidative stress or inflammation could impact graft quality and vulnerability to ischemia-reperfusion injury [9].  

Despite significant progress, several challenges remain. The relatively small sample sizes of many studies can limit the statistical power to detect significant genetic associations. Furthermore, the complex interactions between multiple genes and environmental factors make it challenging to fully elucidate the genetic architecture of transplant rejection. Larger, well-powered studies, including multi-center collaborations, are needed to validate existing findings and identify novel genetic associations. The role of epigenetics, which refers to changes in gene expression without alterations in the DNA sequence, is also an area of growing interest in transplantation [10].  

Future research should focus on several key areas. Larger GWAS and meta-analyses are needed to identify novel genetic variants associated with rejection risk. Integrating genetic data with other clinical and immunological data, such as donor-specific antibodies (DSAs) and immune cell profiling, can provide a more comprehensive understanding of rejection risk and guide personalized immunosuppression. Developing predictive models that incorporate genetic information can help to identify individuals at high risk of rejection and allow for preemptive interventions. Further investigation into the role of non-coding RNAs and other epigenetic mechanisms in transplant rejection is also warranted.

Conclusion

Genetic factors play a significant role in transplant rejection, with both HLA and non-HLA genes contributing to this complex process. Continued research in this area is crucial for developing personalized immunosuppressive strategies, improving long-term graft survival, and ultimately transforming the field of transplantation. Integrating genetic information into clinical practice holds the promise of improving patient outcomes and moving towards a future of precision medicine in transplantation.

Acknowledgement

None

Conflict of Interest

None

References

1. Cypel M, Yeung J, Liu M, Anraku M, Chen F, et al. (2011) . N Engl J Med 364: 1431-1440.

, ,

2. De Perrot M, Liu M, Waddell TK, Keshavjee S (2003) . Am J Respir Crit Care Med 167: 490-511.

, ,

3. Chen F, Date H (2015) . Curr Opin Organ Transplant 20: 515-520.

, ,

4. Liu X, Cao H, Li J, Wang B, Zhang P, et al. (2017) . Cell Death Differ 24: 683-693.

, ,

5. Weyker PD, Webb CAJ, Kiamanesh D, Flynn BC (2012) . Semin Cardiothorac Vasc Anesth 17: 28-43.

, ,

6. Roayaie K, Feng S (2007) Liver Transpl 13: S36-S43.

, ,

7. Bhayani NH, Enomoto LM, Miller JL, Ortenzi G, Kaifi JT, et al. (2014) Morbidity of total pancreatectomy with islet cell auto-transplantation compared to total pancreatectomy alone. HPB (Oxford) 16: 522-527.

Indexed at, Google Scholar, Crossref

8. Morgan KA, Nishimura M, Uflacker R, Adams DB (2011) Percutaneous transhepatic islet cell autotransplantation after pancreatectomy for chronic pancreatitis: a novel approach. HPB (Oxford) 13: 511-516.

Indexed at, Google Scholar, Crossref

9. Jin SM, Oh SH, Kim SK, Jung HS, Choi SH, et al. (2013) Diabetes-free survival in patients who underwent islet autotransplantation after 50% to 60% distal partial pancreatectomy for benign pancreatic tumors. Transplantation 95: 1396-403.

Indexed at, Google Scholar, Crossref

10. Siddiky A (2016) . BMJ 354: i4356.

, ,